Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities (2016 - 2025)

Heron Therapeutics' Cash from Financing Activities history spans 14 years, with the latest figure at $219000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 48.23% year-over-year to $219000.0; the TTM value through Dec 2025 reached $14.4 million, up 1434.79%, while the annual FY2025 figure was $14.4 million, 1434.79% up from the prior year.
  • Cash from Financing Activities reached $219000.0 in Q4 2025 per HRTX's latest filing, down from $13.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $154.7 million in Q2 2021 to a low of -$637000.0 in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $15.0 million, with a median of $371000.0 recorded in 2023.
  • The largest YoY upside for Cash from Financing Activities was 105652.11% in 2022 against a maximum downside of 172.14% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $487000.0 in 2021, then fell by 9.86% to $439000.0 in 2022, then tumbled by 54.67% to $199000.0 in 2023, then soared by 112.56% to $423000.0 in 2024, then crashed by 48.23% to $219000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Cash from Financing Activities are $219000.0 (Q4 2025), $13.4 million (Q3 2025), and $781000.0 (Q2 2025).